$SRXH

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

SRX Global (AMEX:SRXH) said it acquired a stake in Vistagen Therapeutics (NASDAQ:VTGN). SRXH management stated it believes VTGN shares are undervalued and plans to engage with VTGN’s leadership and board on potential shareholder value initiatives. The disclosure did not specify investment size or terms.

SRX Global said it acquired a stake in Vistagen Therapeutics, adding that it believes Vistagen shares are undervalued. SRX plans to engage with Vistagen’s leadership and board to discuss ways to unlock shareholder value, according to the company’s statement.

SRX Global Inc. (SRXH) said it acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage neuroscience biopharma developing intranasal “pherines” for CNS disorders. SRXH said it views VTGN as undervalued and plans constructive engagement with management and the board. VTGN closed at $0.24 and was $0.37 in pre-market.

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001471727 0001471727 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001471727 0001471727 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

SRX Global Inc. (NYSE American: SRXH) reported paper-traded EMJX crypto-treasury returns of about 24.8% (time-weighted) from Feb. 11 to July 10, 2026, versus Bitcoin at -4.2% over the same period. The EMJX regime model shifts among Bull, Mixed, and Stress and will start trading with real capital after an acquisition. Management plans a July 14 fireside chat.

SRX Global, Inc. (NYSE American: SRXH) said CEO Kent Cunningham and President Eric Jackson will host a virtual fireside chat on July 14, 2026 at 10:30 a.m. ET to discuss developments and the completed EMJX acquisition. In a shareholder letter, the company cited $55 million+ cash and short-term investments, no debt, net asset value about $3.07 per share, plus a repurchase plan for up to 10 million shares and a dividend totaling about $1 million.

SRX Global Inc. (NYSE American: SRXH) said its board authorized a share repurchase plan to buy up to 10 million shares or as much as 50% of shares outstanding. The company allocated up to $20 million for repurchases through July 9, 2027, funded by cash on hand, with timing dependent on market and other factors.

SRX Global Inc. (SRXH) reported preliminary balance sheet results after acquiring EMJX and completing a 1-for-60 reverse stock split on July 6, 2026. As of June 30, 2026, it estimated net asset value at about $60 million, or $3.07 per share, with about $40 million cash, over $15 million in short-term investments, and no debt. SRXH shares outstanding were about 19.5 million post-split.